Cheap Enough

What is hurting Indian pharma more—misinformation or price control?

The industry body is lashing out at the regulator for stifling a growing industry. But the members say the drug companies are doing just fine

nose-156596_1280.png

On 13 April, a day before the Easter weekend, many drug manufacturers went on their breaks feeling a little agitated but mostly helpless. It was the day, the spokesperson of the Indian Pharmaceutical Alliance (IPA), representing its (invite only) members—over 20 large companies including Sun Pharma, Dr Reddy’s, Lupin and Cipla—went public with his anger.

Dilip G Shah referred to the pricing policy roll-out as “arbitrary”, and compliance to guidelines “difficult”. Shah claimed these two factors were adding to the “woes” of the drug industry.

To access this content, you must purchase Monthly Recurring or Quarterly, or log in if you are a member.

Sign up to read this story
for free right away

Stories on The Ken are available only for its subscribers. This story is shared with you for free, just sign up to get instant access.

Have an account?

Related stories

More stories in /Healthcare & /Reportage

See all in Healthcare & Reportage

Sign up for free to read this story right now. Sign up for free

Sign up to read this story for free right away

Stories on The Ken are available only for its subscribers. This story is shared with you for free, just sign up to get instant access.

Why should I pay for reading your stories?

Lots of effort We go to lengths to put in time and resources required to get the most factual, honest stories out there.

Advertising independent Our primary allegiance will always be to our readers. We won't be swayed by our advertisers and investors.

We can't do all of this by giving away our journalism for free and selling our readers by the thousands to advertisers.

Get premium access